1. Introduction
===============

Marine invertebrates, especially gorgonian octocorals, have been proven to be rich and important sources of natural products as lead compounds in drug discovery. Members of the gorgonians, *Junceella* and *Briareum*, have yielded numerous and highly oxygenated briarane-type diterpenes with a γ-lactone ring, produced from 3,8-cyclized cembranoids \[[@B1-marinedrugs-11-02042],[@B2-marinedrugs-11-02042],[@B3-marinedrugs-11-02042]\]. Many of the briarane diterpenoids have been reported to exhibit interesting biological activities, such as cytotoxic \[[@B4-marinedrugs-11-02042],[@B5-marinedrugs-11-02042],[@B6-marinedrugs-11-02042]\], anti-inflammatory \[[@B7-marinedrugs-11-02042],[@B8-marinedrugs-11-02042]\], antiviral \[[@B8-marinedrugs-11-02042]\], insecticidal \[[@B9-marinedrugs-11-02042]\] and immunomodulatory \[[@B10-marinedrugs-11-02042]\] activities. Our previous chemical investigation of the genus *Junceella* has resulted in the isolation of over 20 briaranes, including frajunolides A--O and juncenolides A--O \[[@B11-marinedrugs-11-02042],[@B12-marinedrugs-11-02042],[@B13-marinedrugs-11-02042],[@B14-marinedrugs-11-02042],[@B15-marinedrugs-11-02042],[@B16-marinedrugs-11-02042],[@B17-marinedrugs-11-02042],[@B18-marinedrugs-11-02042]\]. As part of our continuing search for bioactive natural products, the chemical constituents from other chromatographic fractions of *J. fragilis* were investigated. Herein, we report the isolation and structural elucidation of four additional new 8-hydroxybriarane diterpenoids, frajunolides P--S ([Figure 1](#marinedrugs-11-02042-f001){ref-type="fig"}, **1**--**4**), from the acetone extract of this source, collected from the southeast coast of Taiwan. Their anti-inflammatory activities were tested and evaluated by superoxide anion generation and elastase release by human neutrophils in response to formylmethionylleucyl-phenylalanine/dihydrocytochalasin B (fMLP/CB).

![Frajunolides P--S (**1**--**4**) isolated from gorgonian *J. fragilis*.](marinedrugs-11-02042-g001){#marinedrugs-11-02042-f001}

2. Results and Discussion
=========================

Compound **1**, \[α\]~D~^25^ +4 (*c* 0.5 CH~2~Cl~2~), was isolated as colorless prisms and had a molecular formula of C~30~H~42~O~11~ deduced from HRESIMS (*m/z* 601.2620 \[M + Na\]^+^, calcd. for C~30~H~42~O~11~Na, 601.2625), indicating ten degrees of unsaturation. The IR spectrum of compound **1** exhibited diagnostic absorption bands of hydroxyl (3443 cm^−1^), γ-lactone (1776 cm^−1^), ester carbonyl (1722 cm^−1^) and conjugated ketone (1655 cm^−1^) functionalities. The ^1^H and ^13^C NMR spectroscopic data ([Table 1](#marinedrugs-11-02042-t001){ref-type="table"}, [Table 2](#marinedrugs-11-02042-t002){ref-type="table"}) indicated the presence of a methyl singlet (δ~H~ 1.08; δ~C~ 16.5, C-15), a methyl doublet (δ~H~ 1.19, *J* = 7.0 Hz; δ~C~ 8.5, C-19), one exocyclic double bond (δ~H~ 5.02, 4.98, each s, H~2~-20; δ~C~ 112.5, C-20; δ~C~ 149.7, C-11), one trisubstituted double bond (δ~H~ 6.89, d, *J* = 9.6 Hz, H-6; δ~C~ 134.5, C-5; 136.8, C-6), four oxygenated methine protons and carbons, (δ~H~ 5.11, d, *J* = 7.6 Hz; δ~C~ 75.6, C-2; δ~H~ 5.31, d, *J* = 9.6 Hz; δ~C~ 78.3, C-7; δ~H~ 5.60, d, *J* = 2.8 Hz; δ~C~ 72.8, C-9; δ~H~ 4.64, t, *J* = 2.8 Hz; δ~C~ 74.1, C-14), an oxygenated quaternary carbon (δ~C~ 83.5, C-8), four methylene carbons (δ~C~ 32.3, 24.1, 31.4, 28.9) and two methine carbons (δ~C~ 43.9 and 44.7), together with a conjugated ester carbonyl (δ~C~ 166.8, C-16) and γ-lactone carbonyl carbon (δ~C~ 174.4, C-19). Detailed analysis of spectroscopic data of **1** and comparison with the related structures of the genus *Junceella* suggested that compound **1** is a highly oxygenated briarane-type diterpenoid with a fused γ-lactone ring similar to juncenolide O, previously isolated from *J. juncea* \[[@B18-marinedrugs-11-02042]\]. In addition, the remaining NMR spectroscopic data contained a methoxy group (δ~H~ 3.81), two acetate groups (δ~H~ 2.20, 1.92, each 3H) and a pivaloyloxy group (δ~H~ 1.38 × 3, 9H). Furthermore, the HMBC correlation showed that the latter was located at C-2, while the acetyl groups were located at C-9 and C-14, and the methoxy group was attached at C-16. The complete planar structure of **1** was further confirmed by the ^1^H--^1^H COSY and HMBC correlations ([Figure 2](#marinedrugs-11-02042-f002){ref-type="fig"}).
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###### 

^1^H-NMR spectroscopic data for compounds **1**--**4**. (δ in ppm, *J* in Hz).

  No.                       1                     2                      3                           4
  ------------------------- --------------------- ---------------------- --------------------------- ----------------------------------
  2                         5.11 (d, *J* = 7.6)   5.00 (m)               4.83 (d, *J* = 9.2)         5.33 (d, *J* = 9.2)
  3                         2.53 (m)              2.48 (m)               3.40 (dd, *J* = 9.6, 3.6)   5.57 (dd, *J* = 10.4, 9.6)
                            1.80 (m)              1.81 (m)                                           
  4                         2.52 (m)              2.81 (m)               4.08 (d, *J* = 3.6)         6.30 (d, *J* = 10.4)
                            2.74 (m)              2.51 (m)                                           
  6                         6.89 (d, *J* = 9.6)   6.84 (d, *J* = 10.0)   \-                          5.96 (d, *J* = 8.8)
  7                         5.31 (d, *J* = 9.6)   5.32 (d, *J* = 10.0)   5.41 (s)                    4.91 (d, *J* = 8.8)
  9                         5.60 (d, *J* = 2.8)   5.56 (d, *J* = 3.5)    5.64 (d, *J* = 8.0)         4.68 (d, *J* = 5.2)
  10                        3.38 (d, *J* = 2.8)   3.27 (d,*J* = 3.5)     2.49 (d, *J* = 8.0)         3.02 (d, *J* = 5.2)
  12                        2.23 (m)              2.25 (m, 2H)           2.18 (m)                    2.47 (td, *J* = 12.4, 1.6)
                            1.80 (m)              \-                     1.78 (m)                    1.32 (dd, *J* = 13.2, 3.6)
  13                        1.80 (m)              1.81 (m, 2H)           2.30 (m)                    4.95 (ddd, *J* = 12.8, 4.0, 2.8)
                            1.40 (m)                                     1.12 (m)                    
  14                        4.64 (t, *J* = 2.8)   4.71 (t, *J* = 3.5)    4.88 (d, *J* = 5.2)         5.18 (br s)
  15                        1.08 (s)              1.25 (s)               1.24 (s)                    1.09 (s)
  16                        \-                    \-                     4.57 (dd,*J* = 12.4, 8.8)   4.56 (s, 2H)
                            \-                    \-                     4.31 (dd,*J* = 12.4, 6.0)   \-
  17                        2.63 (q, *J* = 7.2)   2.60 (q, *J* = 7.0)    2.26 (q, *J* = 7.2)         2.26 (q, *J* = 6.8)
  19                        1.19 (d, *J* = 7.2)   1.19 (d, *J* = 7.0)    1.22 (d, *J* = 7.2)         1.12 (d, *J* = 6.8)
  20                        5.02 (s)              5.04 (s)               2.98 (d, *J* = 4.4)         3.52 (br s)
                            4.98 (s)              4.99 (s)               2.80 (d, *J* = 4.0)         2.72 (d, *J* = 2.4)
  2-OCOC[H]{.ul}~3~         1.92 (s)              1.97 (s)               2.10 (s)                    1.93 (s)
  9-OCOC[H]{.ul}~3~         2.20 (s)              2.23 (s)               2.24 (s)                    2.16 (s)
  13-OCOC[H]{.ul}~3~        \-                    \-                     \-                          2.07 (s)
  14-OCOC[H]{.ul}~3~        \-                    1.93 (s)               1.96 (s)                    1.95 (s)
  2-OCOC(C[H]{.ul}~3~)~3~   1.38 (s, 9H)          \-                     \-                          \-
  16-OC[H]{.ul}~3~          3.81 (s)              3.82 (s)               \-                          \-
  8-OH                      \-                    \-                     5.86 br s                   \-
  16-OH                     \-                    \-                     3.72 (dd, *J* = 8.0, 6.0)   \-
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###### 

^13^C-NMR spectroscopic data for compounds **1**--**4** (δ in ppm, mult).

  No.                       1           2           3           4
  ------------------------- ----------- ----------- ----------- -----------
  1                         48.8 (s)    47.4 (s)    44.7 (s)    46.4 (s)
  2                         75.6(d)     73.6 (d)    75.9 (d)    74.1 (d)
  3                         32.3 (tH)   30.9 (t)    58.7 (d)    131.7 (d)
  4                         24.1 (t)    22.8 (t)    59.0 (d)    128.0 (d)
  5                         134.5 (s)   134.2 (s)   135.7 (s)   139.9 (s)
  6                         136.8 (d)   138.1 (d)   132.4 (d)   126.0 (d)
  7                         78.3 (d)    77.5 (d)    75.7 (d)    78.4 (d)
  8                         83.5 (s)    83.5 (s)    81.2 (s)    80.8 (s)
  9                         72.8 (d)    72.8 (d)    66.8 (d)    64.2 (d)
  10                        43.9 (d)    43.2 (d)    40.2 (d)    37.4 (d)
  11                        149.7 (s)   150.5 (s)   61.2 (s)    58.1 (s)
  12                        31.4 (t)    29.4 (t)    24.1 (t)    34.2 (t)
  13                        28.9 (t)    27.3 (t)    24.3 (t)    67.6 (d)
  14                        74.1 (d)    74.8 (d)    72.7 (d)    73.7 (d)
  15                        16.5 (q)    15.0 (q)    14.7 (q)    14.3 (q)
  16                        166.8 (s)   168.0 (s)   58.8 (s)    44.6 (s)
  17                        44.7 (d)    42.9 (d)    42.9 (d)    43.8 (d)
  18                        174.4 (s)   175.4 (s)   174.8 (s)   175.2 (s)
  19                        8.5 (q)     6.6 (q)     6.4 (q)     6.3 (q)
  20                        112.5 (d)   112.7 (d)   58.4 (t)    50.1 (t)
  2-O[C]{.ul}OCH~3~         \-          170.0 (s)   171.2 (s)   170.0 (s)
  2-OCO[C]{.ul}H~3~         \-          20.9 (q)    20.9 (q)    20.8 (q)
  9-O[C]{.ul}OCH~3~         168.3 (s)   169.3 (s)   169.2 (s)   170.2 (s)
  9-OCO[C]{.ul}H~3~         23.3 (q)    21.7 (q)    21.9 (q)    21.5 (q)
  13-O[C]{.ul}OCH~3~        \-          \-          \-          170.2 (s)
  13-OCO[C]{.ul}H~3~        \-          \-          \-          21.0 (q)
  14-O[C]{.ul}OCH~3~        169.6 (s)   170.5 (s)   170.2 (s)   170.0 (s)
  14-OCO[C]{.ul}H~3~        23.0 (q)    21.2 (q)    21.0 (q)    21.3 (q)
  2-O[C]{.ul}OC(CH~3~)~3~   174.7 (s)   \-          \-          \-
  2-OCO[C]{.ul}(CH~3~)~3~   \- ^a^      \-          \-          \-
  2-OCOC([C]{.ul}H~3~)~3~   28.0 (q)    \-          \-          \-
  16-O[C]{.ul}H~3~          53.6 (q)    52.5 (q)    \-          \-

^a^ Signal not observed.

![^1^H--^1^H COSY and HMBC correlations of compounds **1**--**4**.](marinedrugs-11-02042-g002){#marinedrugs-11-02042-f002}

The configuration of the Me-15 in naturally occurring briaranes was previously assigned β-orientation, and H-10 was in the α-orientation. In the NOESY spectrum of **1** ([Figure 3](#marinedrugs-11-02042-f003){ref-type="fig"}), correlations of Me-15/H-14, H-10/H-2, H-10/H-9, H-9/Me-19 and H-7/H-17 suggested that H-7, Me-15 and H-17 were all β-oriented, while H-2, H-9 and H-14 were α-disposition. Finally, the absolute configuration of compound **1** was unambiguously established by a single-crystal X-ray diffraction, as illustrated in [Figure 3](#marinedrugs-11-02042-f003){ref-type="fig"}. Hence, compound **1** was determined as (1*S*,2*S*,6*Z*,7*S*,8*R*,9*S*,10*S*,14*S*,17*R*)-2-pivaloyloxy-9,14-diacetoxy-8-hydroxybriaran-5(6)*Z*-dien-18,7-olide, and the name frajunolide P was given.

Compound **2** was isolated as a colorless amorphous gum and had the molecular formula C~27~H~36~O~11~, as determined by HRESIMS and distortionless enhancement by polarization transfer (DEPT) NMR analysis. The presence of a hydroxyl, an ester group and a γ-lactone were consistent with IR absorption bands at 3443, 1736 and 1780 cm^−1^, respectively. It was found that the ^1^H- and ^13^C NMR spectroscopic data ([Table 1](#marinedrugs-11-02042-t001){ref-type="table"}, [Table 2](#marinedrugs-11-02042-t002){ref-type="table"}) were similar to those of compound **1**, except that the pivaloyloxy group at C-2 was replaced by an acetate group (δ~H~ 1.97; δ~C~ 170.0, 20.9). This was confirmed by the HMBC correlation ([Figure 2](#marinedrugs-11-02042-f002){ref-type="fig"}) between H-2 (δ~H~ 5.00) and the carbonyl carbon at δ~C~ 170.0. The planar structure and NMR assignments for **2** were established by detailed analysis of 2D NMR, including ^1^H--^1^H COSY, HMQC and HMBC correlations. The configurations of compound **2** were determined by observation of NOESY correlations and on the basis of biogenetic consideration similar to compound **1**. Therefore, compound **2** was identified as (1*S*,2*S*,6*Z*,7*S*,8*R*,9*S*,10*S*,14*S*,17*R*)-2,9,14-triacetoxy-8-hydroxybriaran-5(6)-dien-18,7-olide and named frajunolide Q.

![Key NOESY correlations and X-ray crystallographic diagram of compound **1**.](marinedrugs-11-02042-g003){#marinedrugs-11-02042-f003}

The molecular formula, C~26~H~33~O~12~Cl, of compound **3** was obtained from the HRESIMS, which showed a *quasi*-molecular ion peak at *m/z* 595.1559 \[M + Na\]^+^. The presence of a chlorine atom was suggested from an isotope ion at *m/z* 597.1536 \[M + Na\]^+^, which exhibited one-third of the relative intensity of the normal ion peak. The IR spectrum showed absorption bands at 3480, 3241, 1782 and 1742 cm^−1^, indicating the presence of two hydroxyl, γ-lactone and ester carbonyl functionalities. The ^1^H and ^13^C NMR spectroscopic data ([Table 1](#marinedrugs-11-02042-t001){ref-type="table"}, [Table 2](#marinedrugs-11-02042-t002){ref-type="table"}) further supported the existence of three acetate groups (δ~C~ 171.2, 170.2, 169.2, 21.9, 21.0, 20.9), assigned to C-2 (δ~C~ 75.9), C-9 (δ~C~ 66.8) and C-14 (δ~C~ 72.7) with the aid of HMBC correlations between H-2 (δ~H~ 4.83, d, *J* = 9.2 Hz), H-9 (δ~H~ 5.64, d, *J* = 8.0 Hz), H-14 (δ~H~ 4.88, d, *J* = 5.2 Hz) and acetate carbonyls, respectively. The remaining ^1^H and ^13^C NMR signals revealed that compound **3** possessed a methyl singlet (δ~H~ 1.24, Me-15), a methyl doublet (δ~H~ 1.22, d, *J* = 7.2 Hz, Me-19), one epoxy ring (δ~C~ 58.7, 59.0; δ~H~ 3.40, dd, *J* = 9.6, 3.6 Hz; 4.08, d, *J* = 3.6 Hz), one spirocyclic oxirane ring (δ~C~ 61.2, 58.4; δ~H~ 2.98, d, *J* = 4.4 Hz), 2.80, d, *J* = 4.0 Hz), one tetrasubstituted double bond (δ~C~ 135.7, 132.4), two methylene carbons (δ~C~ 24.3, 24.1), one oxymethylene (δ~C~ 58.8; δ~H~ 4.57, dd, *J* = 12.4, 8.8 Hz; 4.31, dd, *J* = 12.4, 6.0 Hz), one oxymethine (δ~C~ 75.7; δ~H~ 5.41, s), two methine protons (δ~H~ 2.49, d, *J* = 8.0 Hz; 2.26, q, *J* = 7.2 Hz) and two quaternary carbons (δ~C~ 44.7,C-1; 81.2, C-8), together with γ-lactone carbonyl carbon at δ~C~ 174.4 (C-18). The above observation agreed with a 8-hydroxybriarane with γ-lactone in **3**. The structure was further established by detailed analysis of 2D NMR. The signals of the H-20 showed HMBC correlations ([Figure 2](#marinedrugs-11-02042-f002){ref-type="fig"}) with C-11, C-12 and C-10, indicating an epoxy ring at C-11 (δ~C~ 61.2)/C-20 (δ~C~ 58.4). The other epoxy ring was located at C-3/C-4 by observation of COSY (H-2/H-3/H-4) and HMBC correlations between H-4 and C-5. Finally, the chlorine atom has to be attached to C-6 (δ~C~ 132.4) of the tetrasubstituted double bond. This was confirmed by comparison with the NMR data of briarein F \[[@B19-marinedrugs-11-02042]\]. The configuration of compound **3** ([Figure 4](#marinedrugs-11-02042-f004){ref-type="fig"}) was determined by a NOESY experiment and coupled with molecular model MM2 minimized energy calculation \[[@B20-marinedrugs-11-02042]\]. The NOESY spectrum showed correlations of H-3/H-4, H-7/H-4, H-17 and Me-15/H-14 indicated that H-3, H-4, H-7, H-14, H-17 and Me-15 are all β-orientation, while H-2, H-9 and Me-19 favored α disposition, due to correlations of H-10/H-2, H-9 and H-9/Me-19. Moreover, the configuration at C-11 was assigned as *S*, which was determined by the NOESY correlation of H-10/H-20 and comparison with ^13^C NMR data of the related literature \[[@B21-marinedrugs-11-02042]\]. The above interpretation suggested that compound **3** was a novel 8-hydroxybriarane possessing a chlorine atom at C-6, and thus, the name frajunolide R was given.

![Key NOESY correlations and computer-generated perspective model of compounds **3** and **4**.](marinedrugs-11-02042-g004){#marinedrugs-11-02042-f004}

The HRESIMS of **4** exhibited two *pseudo*-molecular ion peaks at *m/z* 621.1716 \[M + Na\]^+^ and 623.1690 \[M + Na + 2\]^+^, accounting for a chlorine atom in the molecular formula, C~28~H~35~O~12~Cl. The IR spectrum showed absorption bands of a hydroxyl (3467 cm^−1^), a γ-lactone (1780 cm^−1^) and an ester carbonyl (1739 cm^−1^) group. The ^1^H- and ^13^C-NMR spectroscopic data ([Table 1](#marinedrugs-11-02042-t001){ref-type="table"}, [Table 2](#marinedrugs-11-02042-t002){ref-type="table"}) of **4** resembled those of juncenolide B, previously isolated from *J. juncea* \[[@B15-marinedrugs-11-02042]\], suggesting that they were analogs. Detailed analysis of NMR and MS data concluded that the only difference between them was the presence of a chlorine atom at C-16 in **4**, replacing the original hydroxyl group in juncenolide B. This finding was supported by observation of the chemical shift of C-6 at δ~C~ 44.6. The relative configuration of **4** was determined by comparing the proton coupling constants of **4** with those of juncenolide B and NOESY studies. Molecular modeling based on MM2 minimized energy was calculated to confirm the structure as illustrated in [Figure 4](#marinedrugs-11-02042-f004){ref-type="fig"}. Thus, compound **4** was elucidated as a 16-chlorinated derivative of juncenolide B, and the name frajunolide S was given.

Four known briaranes were also isolated and identified as umbraculolide A \[[@B22-marinedrugs-11-02042]\], juncenolide C \[[@B15-marinedrugs-11-02042]\], junceellonoid A \[[@B23-marinedrugs-11-02042]\] and juncin R \[[@B24-marinedrugs-11-02042]\], respectively, by comparison with the spectroscopic data reported in the literature. The anti-inflammatory activities ([Table 3](#marinedrugs-11-02042-t003){ref-type="table"}) of briaranes **1**--**4** were tested and evaluated for their inhibition of elastase release and generation of superoxide anion by human neutrophils in response to fMet-Leu-Phe (fMLP)/cytochalasin B. Compounds **1** and **2** showed moderate inhibitory activities on both superoxide anion generation and elastase release at 10 μg/mL.
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###### 

Effects of compounds on superoxide anion generation and elastase release by human neutrophils in response to formylmethionylleucyl-phenylalanine/dihydrocytochalasin B (fMLP/CB).

  Compound   Superoxide anion    Elastase release
  ---------- ------------------- ------------------
  **1**      32.5 ± 1.5 \*\*\*   35.6 ± 3.2 \*
  **2**      28.7 ± 3.4 \*       34.1 ± 2.9 \*\*
  **3**      9.70 ± 1.3 \*\*     16.0 ± 5.3 \*
  **4**      5.80 ± 3.0          −4.5 ± 3.4

Percentage of inhibition (%) at 10 μg/mL concentration. Results are presented as the mean ± S.E.M. (*n* = 3). \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001 compared with the control value.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

Optical rotations were recorded on a JASCO DIP-1000 polarimeter. IR spectra were measured on Hitachi T-2001 spectrophotometer. LRESIMS and HRESIMS were taken on a JEOL JMS-HX 110 mass spectrometer. The ^1^H, ^13^C NMR, ^1^H--^1^H COSY, HMQC, HMBC and NOESY spectra were recorded on a Varian MR 400 and UNITY INOVA 500 spectrometers. The chemical shifts were given in δ (ppm) and coupling constants in Hz. Silica gel 60 (Merck) was used for column chromatography, and pre-coated silica gel plates (Merck, Kieselgel 60 F-254, 1 mm) were used for preparative TLC. Sephadex LH-20 (Amersham Pharmacia Biotech AB, Sweden) was used for separation. LiChrospher^®^ Si 60 (5 μm, 250-10, Merck, Germany) and LiChrospher^®^ 100 RP-18e (5 μm, 250-10, Merck, Germany) were used for NP-HPLC and RP-HPLC (Hitachi), respectively.

3.2. Animal Material
--------------------

The gorgonian *Junceella fragilis* Ridley (Ellisellidae) was collected in Tai-Tong County, Taiwan, by scuba diving at a depth of 15 m, in February 2006. The fresh gorgonian was immediately frozen after collection and kept at −20 °C until processed. A voucher specimen (WSG-5) was deposited in the School of Pharmacy, College of Medicine, National Taiwan University, Taiwan.

3.3. Extraction and Isolation
-----------------------------

The gorgonian *J. fragilis* (wet, 3.9 kg) was minced and extracted with acetone (3 × 5 L) at room temperature, and the acetone extract was concentrated under vacuum. The crude extract (33 g) was partitioned between EtOAc and H~2~O (1:1). The EtOAc-soluble portion (24 g) was shaken with *n*-hexane-MeOH--H~2~O (4:3:1), and the MeOH layer was evaporated and separated on Sephadex LH-20 to give eight fractions (L1 to L8). Fraction L3 (3 g) was subjected to column chromatography using silica gel and a gradient of *n*-hexane/CH~2~Cl~2~/MeOH to obtain 33 fractions (L3-1 to L3-33). Fraction L3-14 (111 mg) was separated on NP-HPLC using *n*-hexane/CH~2~Cl~2~/MeOH (40:20:1) to yield **1** (3.5 mg) and **2** (1.0 mg). Fraction L3-17 (104 mg) was subjected to RP-HPLC using MeOH/H~2~O/CH~3~CN (70:25:5) to give **4** (7.5 mg), umbraculolide A (18 mg) and junceellonoid A (16 mg). L3-20 (97 mg) was separated on RP HPLC using MeOH/H~2~O/CH~3~CN (70:25:5) to obtain **3** (3.5 mg), junceellolide C (12 mg) and juncin R (2.8 mg).

Frajunolide P (**1**): colorless prisms; \[α\]~D~^24^ +4 (*c* 0.5, CH~2~Cl~2~); IR ν~max~3443, 2934, 1776, 1722, 1655, 1379, 1267, 1220 cm^−1^; ^1^H NMR data (400 MHz, CDCl~3~), see [Table 1](#marinedrugs-11-02042-t001){ref-type="table"}; ^13^C NMR data (100 MHz, CDCl~3~), see [Table 2](#marinedrugs-11-02042-t002){ref-type="table"}; ESIMS *m/z* 601 \[M + Na\]^+^; HRESIMS *m/z* 601.2620 \[M + Na\]^+^ (calcd. for C~30~H~42~O~11~Na, 601.2625).

Frajunolide Q (**2**): colorless amorphous gum; \[α\]~D~^24^ +32 (*c* 0.1, CH~2~Cl~2~); IR ν~max~ 3443, 2923, 1780, 1736, 1645, 1375, 1264, 1219 cm^−1^; ^1^H NMR data (500 MHz, CDCl~3~), see [Table 1](#marinedrugs-11-02042-t001){ref-type="table"}; ^13^C NMR data (125 MHz, CDCl~3~), see [Table 2](#marinedrugs-11-02042-t002){ref-type="table"}; ESIMS *m/z* 559 \[M + Na\]^+^; HRESIMS *m/z* 559.2156 \[M + Na\]^+^ (calcd. for C~27~H~36~O~11~Na, 559.2155).

Frajunolide R (**3**): colorless amorphous gum; \[α\]~D~^24^ +13 (*c* 0.3, CH~2~Cl~2~); IR ν~max~ 3480, 3241, 2926, 2856, 1782, 1742, 1373, 1252, 1212 cm^−1^; ^1^H NMR data (400 MHz, CDCl~3~), see [Table 1](#marinedrugs-11-02042-t001){ref-type="table"}; ^13^C NMR data (100 MHz, CDCl~3~), see [Table 2](#marinedrugs-11-02042-t002){ref-type="table"}; ESIMS *m/z* 595 \[M + Na\]^+^, *m/z* 597 \[M + Na + 2\]^+^; HRESIMS *m/z* 595.1559 \[M + Na\]^+^ (calcd. for C~26~H~33~^35^ClO~12~Na, 595.1558).

Frajunolide S (**4**): colorless amorphous gum; \[α\]~D~^24^ −22.0 (*c* 0.2, CH~2~Cl~2~); IR ν~max~ 3476, 2947, 1780, 1739, 1372, 1250, 1223 cm^−1^; ^1^H NMR data (400 MHz, CDCl~3~), see [Table 1](#marinedrugs-11-02042-t001){ref-type="table"}; ^13^C NMR data (100 MHz, CDCl~3~), see [Table 2](#marinedrugs-11-02042-t002){ref-type="table"}; ESIMS *m/z* 621 \[M + Na\]^+^, *m/z* 623 \[M + Na + 2\]^+^; HRESIMS *m/z* 621.1716 \[M + Na\]^+^ (calcd. for C~28~H~35~^35^ClO~12~Na, 621.1715).

3.4. Single Crystal X-ray Structure Determination of Frajunolide P (**1**)
--------------------------------------------------------------------------

A suitable colorless crystal (0.37 × 0.14 × 0.08 mm^3^) of **1** for diffraction was obtained by simple evaporation from methanol solution. Crystal data: C~30~H~42~O~11~ orthorhombic, *a* = 10.1174(2) Å, *b* = 14.0223(3) Å, *c* =21.0529(5) Å, *V* = 2986.76(11) Å^3^, space group P22~1~2~1~, *Z* = 4, D~calcd~ 1.287 mg/m^3^, λ = 0.71073 Å, μ(Mo Kα) 90.098 mm^−1^, *F*(000) = 1240, *T* = 293(2) K. A total of 18,766 reflections collected, of, which 5275 unique reflections (*R*~int~ = 0.0770) with I \> 2σ(*I*) were used for the analysis. The data was solved using the direct method, and the structure was refined by full-matrix least-squares procedure on *F*^2^ values. The refined structural model converged to a final *R*1 0.0684, *wR*2 0.1808 with goodness-of-fit = 1.036. The final X-ray molecular model is shown in [Figure 3](#marinedrugs-11-02042-f003){ref-type="fig"}.

3.5. Anti-Inflammatory Assays
-----------------------------

### 3.5.1. Human Neutrophils Elastase Release

Degranulation of azurophilic granules was determined by elastase release, as described previously \[[@B25-marinedrugs-11-02042]\]. Experiments were performed using MeO-Suc-Ala-Ala-Pro-Val-*p*-nitroanilide as the elastase substrate. After supplementation with MeO-Suc-Ala-Ala-Pro-Val-*p*-nitroanilide (100 μM), neutrophils (6 × 10^5^ cell/mL) were equilibrated at 37 °C for 2 min and incubated with each test compound for 5 min. Cells were activated by fMLP (100 nM)/CB (0.5 μg/mL), and changes in absorbance at 405 nm were monitored continuously for elastase release. The results are expressed as the percentage of the initial rate of elastase release in the fMLP/CB-activated, test compound-free (DMSO) control system.

### 3.5.2. Human Neutrophil Superoxide Generation

Human neutrophils were obtained by means of dextran sedimentation and Ficoll centrifugation. Superoxide anion production was assayed by monitoring the superoxide dismutase-inhibitable reduction of ferricytochrome *c*. In brief, after supplementation with 0.5 mg/mL ferricytochrome *c* and 1.0 mM Ca^2+^, neutrophils were equilibrated at 37 °C for 2 min and incubated with drugs for 5 min. Cells were activated with 100 nM fMLP for 10 min. When fMLP was used as a stimulant, CB (1 μg/mL) was incubated for 3 min before activation by the peptide (fMLP/CB). Changes in absorbance with the reduction of ferricytochrome *c* at 550 nm were continuously monitored in a double-beam, six-cell positioner spectrophotometer with constant stirring (Hitachi U-3010, Tokyo, Japan). Calculations were based on differences in the reactions with and without superoxide dismutase (SOD, 100 U/mL) divided by the extinction coefficient for the reduction of ferricytochrome *c*.

4. Conclusions
==============

Our continuing investigation on constituents of Taiwanese gorgonian *Junceella fragilis* has resulted in the isolation of eight 8-hydroxybriarane diterpenoids, including four new ones, frajunolides P--S (**1**--**4**). In the anti-inflammatory effects on elastase release and generation of superoxide anion by human neutrophils, compounds **1** and **2** exhibited moderate inhibitory activities.
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